Progressive cardiac involvement in a compound heterozygote Fabry patient: a case report
Related Experiment Video
Updated: Jan 25, 2026

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
Eliza Jeanette McConnell1, James Every2, Michel Tchan3
1Cardiology Department, Royal North Shore Hospital, Sydney, Australia.
Insights
Fabry disease, a genetic disorder, can affect the heart in women. This case shows progressive cardiac issues in a compound heterozygote despite enzyme replacement therapy.
Area of Science:
- Genetics
- Cardiology
- Biochemistry
Background:
- Fabry disease is an X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency.
- Accumulation of sphingolipids affects multiple organs, including the heart.
- Female heterozygotes can experience cardiac involvement, typically milder than in males.
Observation:
- A 71-year-old female compound heterozygote with Fabry disease presented with progressive cardiac symptoms.
- The patient had two distinct mutations (N215S, C202R).
- Cardiac involvement persisted despite enzyme replacement therapy (ERT) with Replagal.
Findings:
- Cardiovascular magnetic resonance (CMR) revealed moderate left ventricular dysfunction and wall thinning.
- Low myocardial native T1 and extensive late gadolinium enhancement with increased T2 were observed.
- Troponin elevation indicated ongoing cardiac damage.
Implications:
- This case highlights progressive cardiac involvement in a compound heterozygote Fabry patient despite ERT.
- Detailed cardiac phenotyping using CMR is crucial for understanding disease progression.
- Further research is needed to optimize ERT strategies for complex Fabry disease genotypes.
Background:
Fabry disease is an X-linked lysosomal storage disorder due to mutations in the gene encoding for alpha-galactosidase A, with subsequent accumulation of complex sphingolipids in multiple organs, including the heart. Female heterozygotes can develop cardiac involvement although this is usually milder and slower to progress compared with male hemizygotes.
Case Summary:
A 71-year-old woman with two separate pathological Fabry mutations (N215S, C202R; compound heterozygote) presented with progressive cardiac involvement despite enzyme replacement therapy (ERT) with Replagal, as demonstrated by troponin elevation and cardiovascular magnetic resonance (CMR) findings: moderate segmental left ventricular dysfunction with wall thinning, low myocardial native T1, and extensive late gadolinium enhancement with co-located increased T2.
Discussion:
We report for the first time, a detailed cardiac phenotype using CMR in a compound heterozygote Fabry patient with progressive cardiac involvement despite ERT.
Related Concept Videos
Data Reporting and Recording
Coordination Compounds and Nomenclature
Molecules and Compounds
Organic Compounds
Elements and Compounds
Elements
Elements are classified as atomic or molecular based on the nature of their basic units. They are unique forms of matter with specific chemical and physical properties that cannot break down into smaller substances by ordinary chemical reactions. There...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

